The Clinical Utility of Precision-Guided Dosing for Adalimumab Therapy Optimization in Inflammatory Bowel Disease: A Clinical Experience Program
Authors:
- Stephen B. HanauerSHStephen B. Hanauer
- Esther A. TorresETEsther A. Torres
- Patricia Aragon-HanPAPatricia Aragon-Han
- Jonathon C. ChapmanJCJonathon C. Chapman
- Arun C. SwaminathASArun C. Swaminath
- Ronen AraiRARonen Arai
- Mandalina ButnariuMBMandalina Butnariu
- Thomas C. LeeTLThomas C. Lee
- Shervin RabizadehSRShervin Rabizadeh
- Morgan CheckMCMorgan Check
- Terrence A. BarrettTBTerrence A. Barrett
- Jana G. HashashJHJana G. Hashash
Open Access
- 27 March 2025
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (4) , 428
Abstract
Background/Objectives: This study aimed to establish the clinical utility of a therapeutic drug monitoring (TDM)-supported, model-informed precision dosing (MIPD) approach (precision-guided dosing [PGD]) by assessing the impact of pharmacokinetic (clearance [CL]) and clinical laboratory parameters on adalimumab (ADA) dosage adjustments during maintenance therapy for inflammatory bowel disease (IBD). Methods: In the EMPOWER study, blood was collected at any time post-ADA injection. Pharmacokinetic (PK) testing was conducted in an accredited lab. Inputs for the PGD test included ADA concentrations, antibodies to ADA, albumin levels, and the current dosing regimen. CL was calculated using nonlinear mixed-effect models. Results were reported to health care providers (HCPs) within 3 days. HCPs’ treatment decisions were recorded and classified as treatment reduction, continuation, intensification, or ADA discontinuation. The physician global assessment (PGA) of disease activity was collected. Relationships between drug concentrations, CL, disease activity, and physician decision-making were assessed using logistic regression. Results: A total of 213 cases were assessed by 21 HCPs. ADA treatment was intensified in 24% and discontinued in 13% of cases. An ADA concentration ≤ 10 μg/mL was associated with a 23.7-fold and 3.0-fold higher likelihood of therapy intensification and PGA > 0, respectively, compared to concentrations > 10 μg/mL. An ADA concentration < 5 μg/mL was associated with a 3.3-fold higher likelihood of treatment discontinuation. CL ≥ 0.318 L/day was associated with a 10.4-fold higher likelihood of therapy intensification. Higher CL (>0.8 L/day) was associated with a 3.5-fold and 4.2-fold higher likelihood of treatment discontinuation and PGA > 0, respectively. Conclusions: PGD enables earlier and precise optimization of ADA dosing by predicting trough levels at any time during the therapy cycle. Optimized dosing to achieve target ADA concentrations and low clearance is crucial to mitigate therapy discontinuation and active disease in IBD patients.Keywords
Funding Information
- Prometheus Laboratories
This publication has 55 references indexed in Scilit:
- Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort studyThe Lancet Gastroenterology & Hepatology, 2024
- IBD disease-modifying therapies: insights from emerging therapeuticsTrends in Molecular Medicine, 2023
- Treatment of Ulcerative Colitis with Steroids (in Whom, How Long, What Dose, What Form)Gastroenterology Clinics of North America, 2020
- Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based studyThe Lancet Gastroenterology & Hepatology, 2020
- How, When, and for Whom Should We Perform Therapeutic Drug Monitoring?Clinical Gastroenterology and Hepatology, 2020
- Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel DiseaseDigestive Diseases and Sciences, 2018
- Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of InfliximabClinical Gastroenterology and Hepatology, 2017
- Treat to Target: A Proposed New Paradigm for the Management of Crohn's DiseaseClinical Gastroenterology and Hepatology, 2015
- Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2012
- Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters CommitteeAmerican Journal of Gastroenterology, 2010